Clinical trials: Complicated Intra-abdominal Infections (cIAI), open to volunteers
Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
The study will evaluate the efficacy and safety of Meropenem and Pralurbactam versus Best Available Therapy in the treatment of Carbapenem-Resistant Enterobacteriaceae Infections.
- Conditions
- Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI), Complicated Urinary Tract Infection (cUTI)
- Trial name
- NCT07089186
- Testing
- Meropenem and Pralurbactam, Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Intra-abdominal Infections
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI
This is a Phase 3, randomized, double-blind, multicenter, positive control study to assess the efficacy, safety, and pharmacokinetics of Meropenem and Pralurbactam compared with Ceftazidime-avibactam in combination with…
- Trial name
- NCT06633718
- Testing
- Meropenem and Pralurbactam, Saline, Ceftazidime-avibactam
- Where
- China
- Volunteers
- 786 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Complicated Intra-abdominal Infections (cIAI)
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to <18 years with cIAI.
- Trial name
- NCT06794541
- Testing
- IV Eravacycline 2mg/kg, IV Eravacycline 1.5mg/kg
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tetraphase Pharmaceuticals, Inc
Complicated Intra-abdominal Infection (cIAI), Systemic Inflammatory Response
Ulinastatin on Systemic Immune-Inflammation in Patients With Complicated Intra-Abdominal Infection
Complicated intra-abdominal infection (cIAI) triggers dysregulated systemic inflammation and immune paralysis leading to high organ failure and death risk.
- Conditions
- Complicated Intra-abdominal Infection (cIAI), Systemic Inflammatory Response, Sepsis, Immune Dysfunction
- Trial name
- UTI-cIAI (NCT07672496)
- Testing
- ulinastatin, Normal Saline (0.9% NaCl)
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Fujian Medical University Union Hospital